Emerging Markets Earnings Roundup: Roche, Johnson & Johnson (Part 1)
This article was originally published in PharmAsia News
Executive Summary
First quarter earnings by early birds Johnson & Johnson and Roche showed familiar currency headwinds in emerging markets and Japan.
You may also be interested in...
J&J Building Case For Co-Administration Of Olysio With Gilead’s Sovaldi
Launched in the U.S. in 2013, Olysio brought in $354 million in worldwide sales during the first quarter, including $291 million in the U.S. Now, J&J will undertake a pair of Phase III trials that could back an sNDA to add co-administration with Sovaldi to the drug’s labeling.
Roche’s Breast Cancer Strategy Paying Off, But Diversification Difficult
Roche’s key HER2 breast cancer franchise boasted a stellar sales performance in the first-quarter – rising 27% in the U.S. alone – and the rest of the cancer business followed suit. But, the loss of schizophrenia candidate bitopertin casts a shadow on the firm’s plans for neuroscience.
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.